Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

MiR-34a expression has an effect for lower risk of metastasis and associates with expression patterns predicting clinical outcome in breast cancer

H Peurala, D Greco, T Heikkinen, S Kaur, J Bartkova, M Jamshidi, K Aittomaki, P Heikkila, J Bartek, C Blomqvist, R Butzow, H Nevanlinna

. 2011 ; 6 (11) : e26122.

Jazyk angličtina Země Spojené státy americké

Perzistentní odkaz   https://www.medvik.cz/link/bmc14073119

MiR-34a acts as a candidate tumour suppressor gene, and its expression is reduced in several cancer types. We aimed to study miR-34a expression in breast cancer and its correlation with tumour characteristics and clinical outcome, and regulatory links with other genes. We analysed miR-34a expression in 1,172 breast tumours on TMAs. 25% of the tumours showed high, 43% medium and 32% low expression of miR-34a. High miR-34a expression associated with poor prognostic factors for breast cancer: positive nodal status (p = 0.006), high tumour grade (p<0.0001), ER-negativity (p = 0.0002), HER2-positivity (p = 0.0002), high proliferation rate (p<0.0001), p53-positivity (p<0.0001), high cyclin E (p<0.0001) and H2AX (p<0.0001). However, multivariate analysis adjusting for conventional prognostic factors indicated that high miR-34a expression in fact associated with a lower risk of recurrence or death from breast cancer (HR = 0.63, 95% CI = 0.41-0.96, p = 0.031). Gene expression analysis by differential miR-34a expression revealed an expression signature with an effect on both the 5-year and 10-year survival of the patients (p<0.001). Functional genomic analysis highlighted a novel regulatory role of the transcription factor MAZ, apart from the known control by p53, on the expression of miR-34a and a number of miR-34a targets. Our findings suggest that while miR-34a expression activation is a marker of aggressive breast tumour phenotype it exerts an independent effect for a lower risk of recurrence or death from breast cancer. We also present an expression signature of 190 genes associated with miR-34a expression. Our analysis for regulatory loops suggest that MAZ and p53 transcription factors co-operate in modulating miR-34a, as well as miR-34a targets involved in several cellular pathways. Taken together, these results suggest that the network of genes co-regulated with and targeted by miR-34a form a group of down-stream effectors that maybe of use in predicting clinical outcome, and that highlight novel regulatory mechanisms in breast cancer.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc14073119
003      
CZ-PrNML
005      
20140926204451.0
007      
ta
008      
140926s2011 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1371/journal.pone.0026122 $2 doi
035    __
$a (PubMed)22102859
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Peurala, H. $u Department of Obstetrics and Gynaecology, Helsinki University Central Hospital, Helsinki, Finland.
245    10
$a MiR-34a expression has an effect for lower risk of metastasis and associates with expression patterns predicting clinical outcome in breast cancer / $c H Peurala, D Greco, T Heikkinen, S Kaur, J Bartkova, M Jamshidi, K Aittomaki, P Heikkila, J Bartek, C Blomqvist, R Butzow, H Nevanlinna
520    9_
$a MiR-34a acts as a candidate tumour suppressor gene, and its expression is reduced in several cancer types. We aimed to study miR-34a expression in breast cancer and its correlation with tumour characteristics and clinical outcome, and regulatory links with other genes. We analysed miR-34a expression in 1,172 breast tumours on TMAs. 25% of the tumours showed high, 43% medium and 32% low expression of miR-34a. High miR-34a expression associated with poor prognostic factors for breast cancer: positive nodal status (p = 0.006), high tumour grade (p<0.0001), ER-negativity (p = 0.0002), HER2-positivity (p = 0.0002), high proliferation rate (p<0.0001), p53-positivity (p<0.0001), high cyclin E (p<0.0001) and H2AX (p<0.0001). However, multivariate analysis adjusting for conventional prognostic factors indicated that high miR-34a expression in fact associated with a lower risk of recurrence or death from breast cancer (HR = 0.63, 95% CI = 0.41-0.96, p = 0.031). Gene expression analysis by differential miR-34a expression revealed an expression signature with an effect on both the 5-year and 10-year survival of the patients (p<0.001). Functional genomic analysis highlighted a novel regulatory role of the transcription factor MAZ, apart from the known control by p53, on the expression of miR-34a and a number of miR-34a targets. Our findings suggest that while miR-34a expression activation is a marker of aggressive breast tumour phenotype it exerts an independent effect for a lower risk of recurrence or death from breast cancer. We also present an expression signature of 190 genes associated with miR-34a expression. Our analysis for regulatory loops suggest that MAZ and p53 transcription factors co-operate in modulating miR-34a, as well as miR-34a targets involved in several cellular pathways. Taken together, these results suggest that the network of genes co-regulated with and targeted by miR-34a form a group of down-stream effectors that maybe of use in predicting clinical outcome, and that highlight novel regulatory mechanisms in breast cancer.
590    __
$a bohemika - dle Pubmed
650    12
$a nádory prsu $x genetika $7 D001943
650    02
$a nádory prsu $x mortalita $7 D001943
650    12
$a nádory prsu $x patologie $7 D001943
650    02
$a duktální karcinom prsu $x genetika $7 D018270
650    02
$a duktální karcinom prsu $x mortalita $7 D018270
650    12
$a duktální karcinom prsu $x sekundární $7 D018270
650    02
$a lobulární karcinom $x genetika $7 D018275
650    02
$a lobulární karcinom $x mortalita $7 D018275
650    12
$a lobulární karcinom $x sekundární $7 D018275
650    02
$a cyklin E $x genetika $7 D019927
650    02
$a DNA vazebné proteiny $x genetika $7 D004268
650    02
$a ženské pohlaví $7 D005260
650    02
$a stanovení celkové genové exprese $7 D020869
650    02
$a histony $x genetika $7 D006657
650    02
$a lidé $7 D006801
650    12
$a mikro RNA $x genetika $7 D035683
650    02
$a lidé středního věku $7 D008875
650    02
$a stupeň nádoru $7 D060787
650    02
$a staging nádorů $7 D009367
650    02
$a Oligonucleotide Array Sequence Analysis
650    02
$a Prognosis
650    02
$a RNA, Messenger $x ge [Genetics]
650    02
$a Receptor, erbB-2 $x ge [Genetics]
650    02
$a Survival Rate
650    02
$a Tissue Array Analysis
650    02
$a Transcription Factors $x ge [Genetics]
650    12
$a Tumor Markers, Biological $x ge [Genetics]
650    02
$a Tumor Suppressor Protein p53 $x ge [Genetics]
700    1_
$a Greco, D.
700    1_
$a Heikkinen, T.
700    1_
$a Kaur, S.
700    1_
$a Bártková, Jiřina $7 xx0094304
700    1_
$a Jamshidi, M.
700    1_
$a Aittomaki, K. $7 gn_A_00002739
700    1_
$a Heikkila, P.
700    1_
$a Bártek, Jiří, $d 1953- $7 xx0046271
700    1_
$a Blomqvis,t C.
700    1_
$a Butzow, R.
700    1_
$a Nevanlinna, H.
773    0_
$t PloS one $g Roč. 6, č. 11 (2011), s. e26122 $p PLoS ONE $x 1932-6203 $w MED00180950
773    0_
$p PLoS ONE $g 6(11):e26122, 2011
910    __
$a ABA008 $y 4 $z 0
990    __
$a 20140926204921 $b ABA008
991    __
$a 20140926204921 $b ABA008
999    __
$a ok $b bmc $g 1041014 $s 872020
BAS    __
$a 3
BMC    __
$a 2011 $b 6 $c 11 $d e26122 $x MED00180950 $i 1932-6203 $m PLoS One $n PLoS One
LZP    __
$a NLK 2014-1/lp

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace